$8.31
1.19% yesterday
Nasdaq, Sep 09, 10:00 pm CET
ISIN
US98401F1057
Symbol
XNCR

Xencor, Inc. Stock price

$8.31
+1.31 18.71% 1M
-5.32 39.03% 6M
-14.67 63.84% YTD
-11.58 58.22% 1Y
-17.59 67.92% 3Y
-28.40 77.36% 5Y
-8.70 51.15% 10Y
-0.03 0.36% 20Y
Nasdaq, Closing price Tue, Sep 09 2025
-0.10 1.19%

Key metrics

Basic
Market capitalization
$579.9m
Enterprise Value
$281.0m
Net debt
positive
Cash
$443.9m
Shares outstanding
71.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.7 | 4.3
EV/Sales
1.8 | 2.1
EV/FCF
negative
P/B
0.9
Financial Health
Equity Ratio
71.2%
Return on Equity
-34.3%
ROCE
-17.2%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$157.1m | $134.9m
EBITDA
$-123.2m | $-213.0m
EBIT
$-134.6m | $-188.3m
Net Income
$-177.9m | $-190.5m
Free Cash Flow
$-140.8m
Growth (TTM | estimate)
Revenue
17.5% | 22.1%
EBITDA
23.5% | -28.1%
EBIT
22.4% | -5.5%
Net Income
-0.3% | 18.1%
Free Cash Flow
-700.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-78.4% | -157.9%
EBIT
-85.7%
Net
-113.2% | -141.2%
Free Cash Flow
-89.7%
More
EPS
$-2.4
FCF per Share
$-2.0
Short interest
19.1%
Employees
250
Rev per Employee
$440.0k
Show more

Is Xencor, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Xencor, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Xencor, Inc. forecast:

16x Buy
89%
1x Hold
6%
1x Sell
6%

Analyst Opinions

18 Analysts have issued a Xencor, Inc. forecast:

Buy
89%
Hold
6%
Sell
6%

Financial data from Xencor, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
157 157
18% 18%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 62 62
4% 4%
40%
- Research and Development Expense 230 230
7% 7%
146%
-123 -123
23% 23%
-78%
- Depreciation and Amortization 11 11
9% 9%
7%
EBIT (Operating Income) EBIT -135 -135
22% 22%
-86%
Net Profit -178 -178
0% 0%
-113%

In millions USD.

Don't miss a Thing! We will send you all news about Xencor, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xencor, Inc. Stock News

Neutral
Business Wire
13 days ago
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences: 2025 Wells Fargo Healthcare Conference Date: Wednesday, September 3, 2025 Presentation Time: 3:00 p.m. ET...
Positive
The Motley Fool
about one month ago
Xencor (XNCR) Q2 Revenue Jumps 82%
Neutral
Business Wire
about one month ago
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2025 and provided recent business and clinical program updates. "Xencor is focused on execution of our clinical studies, evaluating fo...
More Xencor, Inc. News

Company Profile

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Head office United States
CEO Bassil Dahiyat
Employees 250
Founded 1997
Website xencor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today